News coverage about Ritter Pharmaceuticals (NASDAQ:RTTR) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.348769105699 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several brokerages recently weighed in on RTTR. Zacks Investment Research raised shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Tuesday, September 26th. Maxim Group restated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Finally, Chardan Capital lowered their price target on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating for the company in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $2.92.
Shares of Ritter Pharmaceuticals (RTTR) opened at $0.34 on Thursday. Ritter Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $3.75.
Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.14). sell-side analysts forecast that Ritter Pharmaceuticals will post -0.66 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This report was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://stocknewstimes.com/2017/11/23/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-ritter-pharmaceuticals-rttr-share-price.html.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.